Clinical presentation of mesothelioma can be misleading^1-3. To complicate matters further, significant shortcomings are associated with the methods currently used to diagnose mesothelioma^2,3. Pathologists and physicians need a better way to diagnose patients and develop treatment plans in a timely fashion.

miRview® meso is a cutting-edge, microRNA-based molecular diagnostic tool. It is designed to rule out malignant pleural mesothelioma in patients with lung adenocarcinoma and other carcinomas of the lung and pleura who have been exposed to mesothelioma-related substances.
It differentiates mesothelioma from other cancers of the lung and miRview® meso is a cutting-edge, microRNA-based molecular diagnostic tool. It is designed to rule out malignant pleural mesothelioma in patients with lung adenocarcinoma and other carcinomas of the lung and pleura who have been exposed to mesothelioma-related substances. It differentiates mesothelioma from other cancers of the lung and pleura with:

• Accuracy
• Speed
• Simple interpretation
• Quantitative analysis
• Objective results
• Cutting-edge molecular biology

1. Klebe S, Mahar A, Henderson DW, Roggli VL. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review. Mod Pathol. 2008;21(9):1084-1094.
2. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2008;132(3):397-401.
3. Stang A, Pohlabeln H, Müller KM, Jahn I, Giersiepen K, Jöckel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52(1):29-36.